HYDERABAD: Dr Reddys Laboratories Ltd Monday announced it has received the approval of the US Food and Drug Administration to market aspirin and dipyridamole capsules in the USA. Aggrenox is a registered trademark of pharmaceutical major Boehringer Ingelheim, the release said. The Aggrenox brand and the generic drug registered sales of approximatel
MUMBAI: Pharma Major, Dr. Reddy's Laboratories Ltd on Monday announced that it has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private Ltd, an emerging generics pharmaceutical company. Therapiva Private Limited is a joint venture between Omnicare Drugs India
Dr. Reddy s Laboratories Ltd. today announced that it has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private Ltd., an emerging generics pharmaceutical company. Therapiva Private Limited is a joint venture between Omnicare Drugs India Private Limited and L
HYDERABAD, India& PRINCETON, N.J. Dr. Reddy s Laboratories Ltd today announced receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox Capsules in the United States market from the U.S. Food and Drug Administration. The Aggrenox brand and generic had U.S. sales of appro
NEW DELHI- Dr. Reddy's Laboratories Ltd. announced Monday that it has agreed to sell its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private Ltd., an emerging generics pharmaceutical company. Hyderabad- based Therapiva Private is a joint venture between Omnicare Drugs India Private Ltd, a unit of BR Shetty-owned N
Innovent Biologics, Inc., a world-class China- based biopharmaceutical company that develops and commercializes high quality drugs, today announced that its IND application for a combination therapy of IBI308 and IBI305, has been approved by the National Medical Products Administration for clinical development. "China has the highest burden of c
HSINCHU, Taiwan and WUHAN, China, Oct. 15, 2018/ PRNewswire/ JHL Biotech announced today that the National Medical Products Administration of the PRC has approved JHL's Phase I and Phase III Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149, to treat several forms of cancer, including advanced non-squamous non-small-cell l
Mariam M. Al Serkal, Senior Web Reporter. Dubai: The Ministry of Health and Prevention issued a circular on Monday withdrawing a diabetic medicine from the UAE market. Al Amiri said that the Ministry of Health and Prevention is in daily contact with local pharmaceutical factories, the US Food and Drug Administration, the European and Australian Med
The FDA has approved and tentatively approved more generic drugs in FY 2018 than any other year prior, the agency announced Thursday. When I started as FDA commissioner, I made clear that one of my top priorities would be ensuring the agency does all it can to help ensure American patients have access to affordable, quality medicines that meet thei
Alberto Martinez, President and CEO, Mundipharma International Ltd, said: Our biosimilars platform is a key component of our growth strategy and todays acquisition is the obvious next step in us ensuring we remain agile and innovative in the biosimilars space. Enrique Ordieres, President of Infarco the parent company of Cinfa Group, commented: Afte
Samsung Bioepis and Celltrion are competing to become the first Korean company to develop a biosimilar to Avastin, a blockbustger drug for colorectal cancer developed by global pharmaceutical company Roche. According to industry sources on October 10, Celltrion filed earlier this month an application for a phase 3 global clinical trial of Avastin..
The "2018 World's Leading Generic Drug Companies: Capabilities, Goals and Strategies" report has been added to ResearchAndMarkets.com' s offering. This report is part of the Competitive Analysis Series to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation t
The "2018 Worlds Leading Generic Drug Companies: Capabilities, Goals and Strategies" report has been added to ResearchAndMarkets.com' s offering. This report is part of the Competitive Analysis Series to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation to
CAUTIONARY STATEMENT RELATING TO THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This Quarterly Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Quarterly Report may not occur.
Albany, NY 10/12/2018 Global Biosimilars Market: Overview. The global market for biosimilars is projected to grow at a significant rate in the coming few years, owing to the low cost of these products. With the growing focus on research and development activities, the market is expected to generate promising opportunities in the next few year
Advisers to the FDA, sitting on its Oncologic Drugs Advisory Committee voted 16-0 in favour of approval of CT-P10, Celltrions biosimilar of Rituxan, following a glowing review by the regulators staff reviewers. Rituxans US patent expired this year, meaning that Teva and Celltrion will likely be able to launch their biosimilar shortly after any deci
South Korean biopharma company Celltrion is on track toward launching its Rituxan biosimilar in the US market, as the drug has obtained the endorsement of the US Food and Drug Administrations drug advisory committee. Celltrion and its marketing partner Teva Pharmaceutical Industries said Thursday that the US FDAs Oncologic Drugs Advisory Committee.
Toronto, Ontario- Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of an aggregate of 17,391,305 units.
HOLZKIRCHEN, Germany, Oct. 11 Sandoz, a division of Novartis, issued the following news release:. Sandoz, a Novartis division and the global leader in biosimilars, today announced a global resolution of all intellectual property related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz (R) for reference medicine Humira (R)*
Today, California Attorney General Xavier Becerra, along with the U.S. Department of Justice and a multistate coalition, announced a settlement in the CVS Health and Aetna merger. The settlement requires Aetna to sell the Medicare Part D plans of 1.5 million people to their competitor, WellCare Health Plans, to ensure competition in the prescriptio
AbbVie, a research-based global biopharmaceutical company, announced today a global resolution of all intellectual property-related litigation with Sandoz over its proposed biosimilar adalimumab product. The license period will begin on September 30, 2023 in the U.S., and will not be accelerated by the entry of companies who have already taken a
Universal Active Pharmaceutical Ingredients Market 2018 Research Report Implements a Comprehensive Study on Market Research Future. The Restraints that are likely to hamper the Growth of Active Pharmaceutical Ingredients market. Once a stronghold of Europe, this market is now slowly shifting towards Asia Pacific.
By a News Reporter-Staff News Editor at Biotech Business Week ANI Pharmaceuticals, Inc. announced the launch of Candesartan Hydrochlorothiazide Tablets, 16 mg/12. 5 mg, 32 mg/12. 5 mg, and 32 mg/25mg, an authorized generic of Atacand HCT . The current annual U.S. market for this product is approximately $20 million, according to Iqvia/IMS Healt
Global Bevacizumab Biosimilar Market Research Report 2018offers elaborated knowledge on the market parts like size, Key Regions, growth, trends, dominating firms, Major Manufactures. The report alsoanalyzeinnovative busi...